Abstract | OBJECTIVE: METHODS: RESULTS: The observed frequencies of the variant alleles CYP2B6*5, CYP2C19*2, CYP2C9*2, and CYP3A5*3 were 12.1%, 25.0%, 4.0%, and 75.8%, respectively. Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received. In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051). CONCLUSION:
|
Authors | Kazuki Takada, Million Arefayene, Zeruesenay Desta, Cheryl H Yarboro, Dimitrios T Boumpas, James E Balow, David A Flockhart, Gabor G Illei |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 50
Issue 7
Pg. 2202-10
(Jul 2004)
ISSN: 0004-3591 [Print] United States |
PMID | 15248218
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antirheumatic Agents
- Cyclophosphamide
- Cytochrome P-450 Enzyme System
|
Topics |
- Adult
- Alleles
- Antirheumatic Agents
(administration & dosage, adverse effects)
- Cohort Studies
- Cyclophosphamide
(administration & dosage, adverse effects)
- Cytochrome P-450 Enzyme System
(genetics)
- Female
- Gene Frequency
- Genetic Variation
- Genotype
- Homozygote
- Humans
- Kidney Failure, Chronic
(etiology)
- Lupus Nephritis
(complications, drug therapy)
- Male
- Middle Aged
- Polymorphism, Genetic
- Predictive Value of Tests
- Primary Ovarian Insufficiency
(chemically induced)
- Pulse Therapy, Drug
- Retrospective Studies
- Risk Factors
- Treatment Outcome
|